ADC Therapeutics SA (ADCT)

NYSE: ADCT · IEX Real-Time Price · USD
16.11 0.66 (4.27%)
Jan 25, 2022 4:00 PM EST - Market closed
Market Cap1.24B
Revenue (ttm)16,907
Net Income (ttm)-56.12M
Shares Out76.72M
EPS (ttm)-3.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume236,229
Open15.44
Previous Close15.45
Day's Range15.35 - 16.74
52-Week Range13.34 - 34.10
Betan/a
AnalystsStrong Buy
Price Target43.71 (+171.3%)
Earnings Daten/a

About ADCT

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in com...

IndustryCommunications Equipment
IPO DateMay 15, 2020
Employees208
Stock ExchangeNYSE
Ticker SymbolADCT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price forecast is 43.71, which is an increase of 171.32% from the latest price.

Price Target
$43.71
(171.32% upside)
Analyst Consensus: Strong Buy

News

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

5 days ago - Business Wire

ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan

ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta (loncastuximab tesirine-lpyl) for all hematolo...

1 week ago - Benzinga

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Z...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

1 week ago - Business Wire

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

2 months ago - Business Wire

ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

2 months ago - Business Wire

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

2 months ago - Business Wire

Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

2 months ago - Business Wire

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

2 months ago - Business Wire

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for D...

BOSTON & SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first p...

3 months ago - Business Wire

ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

3 months ago - Business Wire

ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

4 months ago - Business Wire

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

4 months ago - Business Wire

ADC Therapeutics Announces Medical Leadership Transition

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

4 months ago - Business Wire

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

4 months ago - Business Wire

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

5 months ago - Business Wire

ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

5 months ago - Business Wire

ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

7 months ago - Business Wire

ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

7 months ago - Business Wire

ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

7 months ago - Business Wire

ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

7 months ago - Business Wire

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

7 months ago - Business Wire